Substance / Medication

Escitalopram oxalate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
The therapeutic effects and safety of bright light therapy combined with escitalopram oxalate on insomnia in patients with poststroke depression.
Xiao Meijuan, Feng Liang, Wang Qiongzhang et al. · Int J Geriatr Psychiatry · 2021
PMID: 32830332RCT
Bioequivalence of two commercial preparations of escitalopram oxalate/clonazepam using a liquid chromatography-electrospray mass spectrometry method.
Agarwal Sangita, Gowda Kadajji Veeran, Selvan Perumal Senthamil et al. · Arzneimittelforschung · 2008
PMID: 19137905Observational
Escitalopram oxalate (Lexapro)-induced acneiform eruption.
Khanna Sarika, Chirinos Rodolfo E, Venna Suraj · J Am Acad Dermatol · 2012
PMID: 23158626Case Report
Escitalopram oxalate improved insomnia by targeting SLC6A4 to regulate the hypothalamic-pituitary-adrenal axis.
Gu Xin, An Jing, Zhang Mingxue et al. · Pharmacology · 2026
PMID: 41528928Other
A Novel Green Lithium Oxide Nanoparticle for Adsorption of the Escitalopram Oxalate andSafety Profile.
Loureiro Sthéfany Nunes, Oviedo Leandro Rodrigues, Druzian Daniel Moro et al. · ACS Omega · 2025
PMID: 41018609OtherFull text (PMC)
The selective serotonin reuptake inhibitor escitalopram oxalate negatively impacts the fracture healing in healthy adults and in osteoporotic rats.
Carminati Shimano Roberta, Zamarioli Ariane, Macedo Ana Paula et al. · Sci Rep · 2025
PMID: 41162407PreclinicalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Escitalopram oxalate (substance)
SNOMED CT
412384000
UMLS CUI
C1170746

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.